fda warning letters glp-1 compounders september 2025 8, 2025: launches an import alert listing safe manufacturers – Partnership for Safe Medicines Trends In FDA FY 2025

Psoriasis and inflammatory skin conditions : Small studies have explored GLP-1 receptor agonists in psoriasis, an inflammatory skin condition often associated with metabolic syndrome

The bifurcated nature of current litigation (with gastrointestinal claims proceeding federally and vision loss claims advancing through state courts) creates pressure on manufacturers from multiple directions simultaneously, increasing the likelihood that Novo Nordisk and Eli Lilly will eventually pursue comprehensive settlement frameworks addressing both injury types

Let's break down what can be missing from that attractive low number you saw in an ad

Compounded drugs are not FDA approved and do not undergo FDA safety, efficacy, or quality review.

The ITT was conducted one week following the GTT, and rats were injected intraperitoneally with insulin (0.75 U/kg)

Trends in Endocrinology & Metabolism